Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ

Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review for the U.S. Preventive Services Task Force

(2013) Heidi D. Nelson et al.   ANNALS OF INTERNAL MEDICINE

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

(2013) Jack Cuzick et al.   LANCET

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010

(2012) Erika A. Waters et al.   BREAST CANCER RESEARCH AND TREATMENT

Women’s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid

(2011) Angela Fagerlin et al.   BREAST CANCER RESEARCH AND TREATMENT

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

(2011) Andrew N. Freedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women

(2011) Rayna K. Matsuno et al.   JNCI-Journal of the National Cancer Institute

Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS

(2011) I. L. Wapnir et al.   JNCI-Journal of the National Cancer Institute

Preventive therapy for breast cancer: a consensus statement

(2011) Jack Cuzick et al.   LANCET ONCOLOGY

Exemestane for Breast-Cancer Prevention in Postmenopausal Women

(2011) Paul E. Goss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Implementation in a Large Health System of a Program to Identify Women at High Risk for Breast Cancer

(2011) William L. Owens et al.   Journal of Oncology Practice

Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ

(2010) Brian L. Sprague et al.   BREAST CANCER RESEARCH AND TREATMENT

Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial

(2010) Christian R. Loehberg et al.   BREAST CANCER RESEARCH AND TREATMENT

Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among U.S. Women

(2010) E. A. Waters et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Integrating Tools for Breast Cancer Risk Assessment, Risk Reduction, and Early Detection

(2010) E. M. Ward et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

The Lack, Need, and Opportunities for Decision-Making and Informational Tools to Educate Primary-Care Physicians and Women about Breast Cancer Chemoprevention

(2010) P. M. Ravdin   Cancer Prevention Research

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

(2010) V. G. Vogel et al.   Cancer Prevention Research

Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-Analysis

(2010) Mary E. Ropka et al.   JOURNAL OF CLINICAL ONCOLOGY

Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid

(2009) Angela Fagerlin et al.   BREAST CANCER RESEARCH AND TREATMENT

American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction

(2009) Sarah Temin   GYNECOLOGIC ONCOLOGY

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

(2009) Kala Visvanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users

(2008) Gabriella Rondanina et al.   JOURNAL OF CLINICAL ONCOLOGY